Oncology Update

Oncology Update

Michael Smart

education
ONF 2011, 39(1), 109-110. DOI: 10.1188/12.ONF.109-110

Cetuximab (Erbitux®) has been approved by the U.S. Food and Drug Administration (FDA) in combination with standard chemotherapy (a platinum plus 5-fluorouracil) for first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Members Only
Not a current ONS member or journal subscriber?

Become a Member

Explore the benefits of membership.
Join ONS or Renew Membership

Purchase This Article

Receive a PDF to download and print.